Idorsia's Clozel says recruitment delay won't dent Fabry drug prospects

Fledgling Swiss biotech Idorsia has suffered delays in recruiting patients for a key trial of its experimental lucerastat drug but that will not damage its commercial prospects, founder Jean-Paul Clozel told Reuters on Tuesday.